First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Excision of HIF1α decreases viral reactivation from latency in infected splenocytes in vivo. by Darlah M. López-Rodríguez (8098544)

ROC curve and P-R curve (attack traffic proportion = 50%). by Longyan Ran (18452261)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

Competition localization increases with growth rate or the distances between colonies, and decreases with the resource diffusion constant. by Jeremy M. Chacón (8259792)

Abolishing the ordered neuron density gradient decreased the positive correlation observed for axon elongation scaling. by Sarah F. Beul (6008801)

ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

“…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

E₅₀ values of angle. by Junxia Zhou (14381598)

Curve fitting of E₅₀. by Junxia Zhou (14381598)

Fitting curves of E₅₀. by Junxia Zhou (14381598)

E₅₀ values of size. by Junxia Zhou (14381598)

E₅₀ fluctuation coefficient. by Junxia Zhou (14381598)

Fitting relationship of E₅₀. by Junxia Zhou (14381598)

Fitting curve of E₅₀. by Junxia Zhou (14381598)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

“…Pre-treatment spontaneous decrease of RPR titer was associated with a slower decrease in post-treatment RPR titer.…”

Assessment of indicators of vitamin A status in non-cirrhotic chronic hepatitis C patients by R.C. Santana (6516497)

“…Furthermore, more advanced stages of liver fibrosis were related to a decrease in serum vitamin A levels.</p></div>…”